October 24, 2008 - BSD Medical Corp. said the European Journal of Cancer has pre-published in its online edition an article titled "Hyperthermia Adds to Chemotherapy" (EJC 6850) authored by Rolf D. Issels, M.D., Ph.D, of the University Hospital Medical Center Grosshadern and Helmholtz Zentrum Munchen-German Research Center for Environmental Health, Munich Germany.
The article highlights the success from clinical studies of deep regional hyperthermia using the BSD-2000 to treat cancer patients.
The European Journal of Cancer is an international comprehensive oncology journal that publishes original research and review article on clinical oncology (medical, pediatric, radiation and surgical), and on cancer epidemiology and prevention. Central to Dr. Issels article in this prestigious journal is the statement regarding the clinical studies that have been conducted on deep hyperthermia: "At present, we are witnessing the coming of age for regional 'deep' hyperthermia, supported by a wealth of new biological data, the results of clinical trials strengthen the current evidence that hyperthermia combined with chemotherapy is an effective and useful modality which should be integrated in the present cancer treatment armamentarium."
Some of the points addressed by Dr. Issels in the article include:
- Heat multiplies the cytotoxicity of many chemotherapeutic agents
- The treatment strategy of combining chemotherapy with hyperthermia may not only be advantageous to the treatment of cancers, but also may result in a lower risk of treatment-induced secondary cancers by immunogenic effects
- For those drugs that show temperature-dependent enhancement, the rationale for their combined application is that hyperthermia "targets" the action of the chemotherapeutic agent within the tumor region.
For more information: www.bsdmedical.com